Compare DexCom, Inc. (DXCM) vs Howmet Aerospace Inc (HWM) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Howmet Aerospace (HWM) trades at $268.89, down 2.85% on the day but maintains strong bullish technical momentum with consistent earnings beats. The company reported robust Q1 2026 EPS of $1.22, exceeding expectations, driven by commercial aerospace demand. Valuation ratios remain elevated with a P/E of 64.79, reflecting growth premiums. Analyst consensus is overwhelmingly positive with 84% buy ratings and a $317.63 price target, indicating 18% upside potential from current levels.

Outlook remains favorable with aerospace cycle strength and defense contracts supporting revenue growth, though high valuation multiples pose sensitivity risks. Key risks include execution challenges in meeting production targets and macroeconomic pressures on travel demand. The stock's trajectory hinges on Q2 2026 results due August 6, 2026, where another beat could validate premium pricing.